Skip to main content

Table 1 Clinicopathologic and molecular characteristics of colorectal cancers according to the CIMP status

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

  CIMP-low/negative
(n = 211)
CIMP-high
(n = 34)
Pvalue
Age (yrs)    0.388
   Mean ± SD 59.7 ± 11.9 61.6 ± 11.9  
   Median (range) 62.0 (29 - 83) 63.5 (33 - 82)  
Gender (%)    0.752
   Male 118 (55.9) 20 (58.8)  
   Female 93 (44.1) 14 (41.2)  
Tumor site (%)    < 0.001
   Proximal 64 (30.3) 23 (67.6)  
   Distal 147 (69.7) 11 (32.4)  
Lymph node metastasis (%)   0.770
   Absent 106 (50.2) 18 (52.9)  
   Present 105 (49.8) 16 (47.1)  
AJCC stage (%)    0.548
   I/II 100 (47.4) 18 (52.9)  
   III/IV 111 (52.6) 16 (47.1)  
Differentiation (%)    < 0.001
   Well/Moderate 191 (90.5) 21 (61.8)  
   Poor/Mucinous 20 (9.5) 13 (38.2)  
Mucinous histology (%)    0.045...
   Absent 202 (95.7) 28 (82.4)  
   Present 9 (4.3) 6 (17.6)  
BRAF (%)    < 0.001
   Wild type 209 (99.1) 25 (73.5)  
   Mutation 2 (0.9) 9 (26.5)  
KRAS (%)    0.894
   Wild type 139 (65.9) 22 (64.7)  
   Mutation 72 (34.1) 12 (35.3)  
MGMT methylation (%)    < 0.001
   Absent 153 (72.5) 12 (35.3)  
   Present 58 (27.5) 22 (64.7)  
MSI status (%)    < 0.001
   MSS/MSI-low 183 (86.7) 13 (38.2)  
   MSI-high 28 (13.3) 21 (61.8)  
  1. CIMP CpG island methylator phenotype, AJCC American Joint Committee on Cancer, MSI microsatellite instablity, MSS microsatellite stable.
  2. Bold numbers indicate features associated with CIMP-high colorectal cancers p values < 0.05 were adjusted with Bonferroni correction to correct for potential false positive results